312 related articles for article (PubMed ID: 22853318)
1. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Hadji P
Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
[TBL] [Abstract][Full Text] [Related]
2. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
Komm BS; Chines AA
Maturitas; 2012 Mar; 71(3):221-6. PubMed ID: 22196312
[TBL] [Abstract][Full Text] [Related]
3. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
4. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
5. Lasofoxifene in postmenopausal women with osteoporosis.
Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Lewiecki EM
J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
8. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
9. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado Martín PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.
Gennari L; Merlotti D; Nuti R
Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039
[TBL] [Abstract][Full Text] [Related]
12. Use of SERMs for treatment in postmenopausal women.
Pinkerton JV; Thomas S
J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
[TBL] [Abstract][Full Text] [Related]
14. Lasofoxifene in osteoporosis and its place in therapy.
Swan VJ; Hamilton CJ; Jamal SA
Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen modulators in menopause.
Gambacciani M
Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
[TBL] [Abstract][Full Text] [Related]
16. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
17. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
18. Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.
de Villiers TJ
Climacteric; 2009; 12 Suppl 1():108-11. PubMed ID: 19811253
[TBL] [Abstract][Full Text] [Related]
19. Lasofoxifene for postmenopausal women with osteoporosis.
Silva-Fernández L; Andreu JL
N Engl J Med; 2010 Jun; 362(23):2228; author reply 2228-9. PubMed ID: 20568310
[No Abstract] [Full Text] [Related]
20. [Bazedoxifene as a new-generation SERM].
Ohta H
Clin Calcium; 2011 Jan; 21(1):34-42. PubMed ID: 21187592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
